AMENDMENT NO. 1 TO LETTER AGREEMENTDevelopment Program Letter Agreement • March 28th, 2019 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 ("Amendment No. 1") to the Development Program Letter Agreement is entered into and effective as of November 26, 2018 ("Amendment No. 1 Effective Date") by and between Aridis Pharmaceuticals, Inc. ("Aridis") and Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT").
